TEPROTUMUMAB AND ITS IMPACT ON QUALITY OF LIFE IN PATIENTS WITH THYROID EYE DISEASE: A REVIEW

Thyroid eye disease (TED) significantly affects patients' quality of life (QoL), leading to substantial physical, emotional, and social impairments. Teprotumumab, a fully human monoclonal antibody targeting the insulin-like growth factor-1 receptor, has emerged as a novel treatment option for moderate to severe TED. This review explores the mechanism and efficacy of Teprotumumab, its impact on patients' QoL, and the importance of integrating QoL assessments into clinical practice. Current evidence highlights that Teprotumumab not only alleviates ocular symptoms but also enhances overall well-being, emphasizing the need for holistic management strategies in TED. Keywords: Thyroid Eye Disease, Grave’s Disease, Quality of life, Teprotumumab